SHS Gesellschaft für Beteiligungsmanagement mbH
5. March 2018 - SHS News

SHS strengthens network activities in the US – André Zimmermann assumes responsibility for international business development

André Zimmermann has taken on responsibility for the international network activities of Tuebingen-based medical technology investor SHS Gesellschaft für Beteiligungsmanagement mbH. The international business development of SHS focuses on the US healthcare market. SHS invests in healthcare companies in German-speaking countries and is a specialist for growth financing, changes in shareholder structures and successor situations.

The company sees the US healthcare market as particularly attractive. “The US market is very large, dynamic, open for innovations and provides our portfolio companies with many opportunities for further development. The primary goal of expanding our network consists of facilitating access to the US market for our portfolio companies and all future investments, particularly in the fields of medical technology and diagnostics. André Zimmermann has gained extensive experience and expertise in this area. He will be responsible for strengthening our contacts in the USA”, explained Hubertus Leonhardt, managing partner at SHS. Presence in the US market is an important prerequisite for the success of medical technology companies. The right contacts are crucial to market access. “I would like to help make it even easier for the companies in our portfolio to succeed in the USA. To do this, we rely on our proven network and continually establish new contacts. I look forward to the new challenge”, said André Zimmermann, partner at SHS. Working from Tuebingen, Zimmermann will serve as the primary contact especially for multipliers, investors and major US medical technology companies, and work to continuously expand the SHS network in the USA. Zimmermann will be taking on this task in addition to his existing duties and will thus remain responsible for the selection and development of portfolio companies as well as for partnerships with health insurance companies and associations. After training as a banker at Dresdner Bank, Zimmermann studied and received his doctorate in molecular biology while
simultaneously studying economics. He has been an investment manager at SHS since 2002 and a partner since 2010.

In the USA, minimally invasive surgery and robotics are currently trending in the medical technology sector – an area in which SHS has already been active for a long time. Among other investments, the Tuebingen-based investment company’s portfolio includes the heart valve repair specialist CoreMedic, the robotic surgery company AOT and Tyromotion, a specialist for robotics and computer-aided rehabilitation devices.

About SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement is based in Tuebingen, Germany and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. SHS was founded in 1993 and has since gained extensive experience as an industry investor, which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s German and international investors include the European Investment Fund, professional pension insurers, retirement funds, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company is currently investing from its fourth generation of funds, for which investors have provided 125 million euro. Equity of up to 20 million euro is invested. Transactions can be carried out in the mid double-digit million range together with a network of co-investors. Reinhilde Spatscheck, Dr. Bernhard Schirmers, Hubertus Leonhardt and Uwe Steinbacher are the Managing Partners at SHS.

Further information:

PR Contact:
Dr. Reinhard Saller
Ira Wülfing Kommunikation GmbH
Tel.: +49 (0) 89 2000 3038
Fax: +49 (0) 89 2000 3040